Roche renews partnership with Sysmex to deliver haematology testing solutions

This successful long-running partnership continues to evolve and bring haematology testing innovations to laboratories, globally The new agreement aims to utilise the IT systems to lead to improved clinical decision making and customer experience Blood disorders have a high impact, not only for patients but for society as a whole, accounting for a third of... Read more

Fluidigm Receives CE-IVD Mark for Its Saliva-Based Advanta Dx SARS-CoV-2 RT-PCR Assay for COVID-19

Jan 21, 2021 SOUTH SAN FRANCISCO, Calif., Jan. 21, 2021 (GLOBE NEWSWIRE) — Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that the company has received the CE-IVD mark for its Advanta™ Dx SARS-CoV-2 RT-PCR Assay, an extraction-free saliva-based test to detect nucleic acid from the SARS-CoV-2 virus.... Read more

Illumina Wins Patent Infringement Suit against BGI in the UK

SAN DIEGO–(BUSINESS WIRE)–Illumina, Inc. (NASDAQ: ILMN) today announced that the High Court of Justice, Chancery Division, Patents Court, issued a judgment in its favor in the patent infringement suit filed against the BGI Companies, MGI Tech Co. Ltd; Latvia MGI SIA; MGI International Sales Co., Ltd; and BGI Complete Genomics Hong Kong Co., Ltd. The... Read more

Illumina Announces New and Expanded Oncology Partnerships with Bristol Myers Squibb, Kura Oncology, Myriad Genetics, and Merck to Advance Comprehensive Genomic Profiling

SAN DIEGO–(BUSINESS WIRE)–With genetic sequencing at the forefront of precision medicine, Illumina (NASDAQ: ILMN) is pleased to announce a portfolio of new and expanded oncology partnerships that further the company’s commitment to develop standardized, globally distributable tools for precision oncology. Speaking today at the 39th Annual J.P. Morgan Healthcare Conference in San Francisco, California, Illumina... Read more

Thermo Fisher Scientific Offers Financial Flexibility with New Managed Equipment Solutions

Thermo Fisher Scientific Offers Financial Flexibility with New Managed Equipment Solutions New model for instrument and equipment procurement offers customers subscription-based access to technology, and associated consumables, services and support WALTHAM, Mass., Jan. 6, 2021 /PRNewswire/ — Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced the launch of Managed Equipment... Read more

HORIBA Scientific Completes Healthy Business Certification

01/04/2021 NJBIA Certifies HORIBA NJ Office as a Certified Site for Infectious Disease Prevention Piscataway, NJ – January 4th, 2021  HORIBA Scientific, global leader in measurement and analysis solutions for research and industry, is proud to announce that the Piscataway, New Jersey office has completed the requirements of the NJBIA program to achieve the Healthy Business... Read more

Bruker Introduces MBT Sepsityper® Kit US IVD for Rapid and Affordable Identification of over 400 Microorganisms from Positive Blood Cultures

MBT Sepsityper Kit US IVD enables rapid, specific detection of many cases of bacteremia-induced sepsis to assist infectious disease specialists in potentially life-saving decisions Used for MALDI Biotyper® (MBT) identification directly from Positive Blood Cultures (PBC) with short time-to-result (TTR) of less than 30 minutes US FDA clearance received in late December for diagnostic use... Read more

Quanterix Receives FDA Emergency Use Authorization for Semi-quantitative Antibody Test

Infectious Disease Technology Antibody test available on Simoa HD-X Analyzer® detects and quantitates IgG antibodies to SARS-CoV-2 in serum or EDTA plasma   BILLERICA, Mass., December 28, 2020 – Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that the Food and Drug Administration (FDA) has issued an Emergency Use... Read more

FDA approves Roche’s OCREVUS® (ocrelizumab) shorter 2-hour infusion for relapsing and primary progressive multiple sclerosis

Basel, 14 December 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved a shorter two-hour infusion time for OCREVUS® (ocrelizumab), dosed twice-yearly for those living with relapsing or primary progressive multiple sclerosis (MS) who have not experienced any prior serious infusion reactions (IRs). The... Read more